All In Biotech

Drug Trial Radar · NCT04764474

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) Mutations

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

46

Actual

Start

Apr 12, 2021

Primary completion

Jan 15, 2025

Study completion Jan 15, 2025

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Feb 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

Conditions

  • Isocitrate Dehydrogenase Gene Mutation

Interventions

  • HMPL-306Drug

    Administered orally QD in a 28-day continuous dosing treatment cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of HMPL-306Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
  2. Dose Escalation Part: Number of Patients With Dose-Limiting Toxicities (DLTs)Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
  3. Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 25.25 months

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center

    Orange, California

  • Winship Cancer Institute - Emory University

    Atlanta, Georgia

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Froedtert-Medical College of WI

    Milwaukee, Wisconsin

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Institut Catala d'Oncologia de l'Hospitalet de Llobregat - Hospital Duran i Reynals

    Barcelona, Spain

  • START Madrid - Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Valencia, Spain

  • Hospital Universitario La Fe

    Valencia, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.